News
CDNA
84.42
+7.46%
5.86
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
NASDAQ · 3d ago
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 3d ago
Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
Seeking Alpha · 5d ago
Baron Discovery Fund Q3 2026 Portfolio Activity
Seeking Alpha · 5d ago
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
NASDAQ · 6d ago
CareDx Announces Third KOAR Analysis Published in Transplantation
Barchart · 6d ago
Cathie Wood's weekly recap: loads TER, AVAV after strong results; books gain in AMD, TSM, LLY
Seeking Alpha · 11/02 12:05
CareDx price target raised to $90 from $46 at H.C. Wainwright
TipRanks · 11/02 11:10
CareDx Consensus Price Target Increased by 40.49% to $87.89
NASDAQ · 11/02 10:12
Weekly Report: what happened at CDNA last week (1026-1030)?
Weekly Report · 11/02 09:17
Why Is CareDx Stock (CDNA) Up 18% Today?
TipRanks · 10/30 18:01
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/30 17:05
Midday Fly By: Amazon and Intel slide, Binance suffers massive hack
TipRanks · 10/30 15:56
Investors pivot to safety as low-volatility stocks back in spotlight
Seeking Alpha · 10/30 14:19
AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday
Benzinga · 10/30 14:15
CareDx rises 24.4%
TipRanks · 10/30 14:00
CareDx Q3 Revenue Jumps 39%; Raises FY26 Revenue, EBITDA Guidance; Stock Up
NASDAQ · 10/30 11:08
At a glance: stocks gapping up premarket
Seeking Alpha · 10/30 10:46
CareDx Is Maintained at Buy by BTIG
Dow Jones · 10/30 10:36
CareDx Price Target Raised to $92.00/Share From $81.00 by BTIG
Dow Jones · 10/30 10:36
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.